Skinfold thickness for rivastigmine patch application in Alzheimer’s disease

[1] Birks JS(2015)Rivastigmine for Alzheimer’s disease Cochrane Database Syst Rev 9 CD001191-283

[2] Chong LY(2017)Factors affecting therapeutic response to Rivastigmine in Alzheimer’s disease patients in Taiwan Kaohsiung J Med Sci 33 277-864

[3] Grimley Evans J(2012)Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer’s disease patients J Alzheimers Dis 31 857-250

[4] Chen TH(1998)Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease Acta Neurol Scand 97 244-97

[5] Chou MC(1974)Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years Br J Nutr 32 77-166

[6] Lai CL(2004)A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry Biomed Chromatogr 18 160-1682

[7] Wu SJ(1999)Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status Expert Opin Investig Drugs 8 1673-357

[8] Hsu CL(2016)Cerebral white matter changes on therapeutic response to rivastigmine in Alzheimer’s disease J Alzheimers Dis 54 351-653

[9] Yang YH(2009)Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer’s disease Electrophoresis 30 644-805

[10] Chou MC(2009)Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review Int J Clin Pract 63 799-443

[1] Birks JS(2015)Rivastigmine for Alzheimer’s disease Cochrane Database Syst Rev 9 CD001191-283

[2] Chong LY(2017)Factors affecting therapeutic response to Rivastigmine in Alzheimer’s disease patients in Taiwan Kaohsiung J Med Sci 33 277-864

[3] Grimley Evans J(2012)Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer’s disease patients J Alzheimers Dis 31 857-250

[4] Chen TH(1998)Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease Acta Neurol Scand 97 244-97

[5] Chou MC(1974)Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years Br J Nutr 32 77-166

[6] Lai CL(2004)A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry Biomed Chromatogr 18 160-1682

[7] Wu SJ(1999)Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status Expert Opin Investig Drugs 8 1673-357

[8] Hsu CL(2016)Cerebral white matter changes on therapeutic response to rivastigmine in Alzheimer’s disease J Alzheimers Dis 54 351-653

[9] Yang YH(2009)Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer’s disease Electrophoresis 30 644-805

[10] Chou MC(2009)Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review Int J Clin Pract 63 799-443